Holen Sie sich die Stockscreener-App
156.90
0.51%
-0.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca stock after-hours at EUR 141.75: minus 1.05 percent versus prior close - AD HOC NEWS
Employee schemes bring 9,828 new AstraZeneca (AZN) shares to London Stock Exchange trading. - Stock Titan
With no treasury shares, AstraZeneca (AZN) reports 1.55B voting rights. - Stock Titan
AstraZeneca Adds Employee Scheme Shares to London Listing - TipRanks
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform - GlobeNewswire Inc.
AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent. - AD HOC NEWS
AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus - kalkinemedia.com
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 - Yahoo Finance
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – AZN - ACCESS Newswire
AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating - marketscreener.com
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination - reuters.com
AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Sco - GuruFocus
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
A $2 Billion Reason Why AstraZeneca Stock Is Down Today - Barchart.com
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC - Seeking Alpha
AstraZeneca pours $2bn into Summit to advance cancer treatment - BioXconomy
Summit Shares Jump on $2B Strategic Investment From AstraZeneca - TradingView
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push - BioPharma Dive
AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies - Proactive financial news
Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration - marketscreener.com
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com
Rights equivalent to a 12% stake await closing as AstraZeneca (AZN) agrees to invest in Summit. - Stock Titan
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Pharmaceutical Technology
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
AstraZeneca PLC : RBC reaffirms its Buy rating - marketscreener.com
AstraZeneca PLC : JP Morgan maintains a Buy rating - marketscreener.com
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
FTSE 100 rises as AstraZeneca lifts healthcare sector - marketscreener.com
AstraZeneca PLC : Deutsche Bank is Neutral - marketscreener.com
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up - uk.finance.yahoo.com
Analysts back AstraZeneca's $2B Summit Therapeutics investment as stock gains (AZN:NYSE) - Seeking Alpha
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
AstraZeneca takes $2bn stake in Summit Therapeutics to pair up cancer drugs - Proactive Investors
AstraZeneca Invests $2bn In Summit To Accelerate Ivonescimab Development - DirectorsTalk Interviews
AstraZeneca to Buy $2 Billion of New Equity in Summit Therapeutics - marketscreener.com
AstraZeneca PLC submits US NDA for Orpathys plus Tagrisso - Mugglehead Investment Magazine
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca files US FDA application for Hutchmed lung cancer drug combination - marketscreener.com
SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? - Yahoo Finance
AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure? - Yahoo Finance
Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - marketscreener.com
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
AstraZeneca Invests $2 Billion in Summit Therapeutics; Enters Clinical Collaboration - marketscreener.com
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg.com
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs - marketscreener.com
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth? - Yahoo Finance
AstraZeneca PLC Agencies, 1999 - OpenSecrets
AstraZeneca PLC Agencies, 2026 - OpenSecrets
Directors’ Deals: AstraZeneca’s Soriot in a major show of faith - Financial Times
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca Gets FDA Priority Review for IMFINZI Combo - grafa.com
AstraZeneca & Fevertree Drinks: Big director share deals - Investors' Chronicle
AstraZeneca gains EU approval for asthma drug, boosting growth outlook with strong pipeline and oncology focus - Pluang
Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum (NYSE:AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Wins EU Asthma Nod For Trixeo This Week: How Big Is Respiratory Opportunity? - Kalkine Media
AstraZeneca hails US priority review for Imfinzi for bladder cancer - London South East
AstraZeneca stock slips 1.91 percent as earnings estimates rise - AD HOC NEWS
Priority review for AstraZeneca's Imfinzi in bladder cancer - marketscreener.com
AstraZeneca stock gains 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca stock rises 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca PLC Agencies, 2021 - OpenSecrets
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? - Yahoo Finance
AstraZeneca’s New Asthma Care Trial Signals Long-Term Upside for Respiratory Investors - TipRanks
AstraZeneca stock heads into the open after a 2.84 percent drop - AD HOC NEWS
AstraZeneca stock heads into the open after a 1.20 percent drop - ad-hoc-news.de
AstraZeneca stock falls 2.65 percent after the close - AD HOC NEWS
AstraZeneca wins EU label expansion for Trixeo in asthma (AZN) - Seeking Alpha
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):